BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22618520)

  • 1. Nitroglycerine use in transcatheter arterial (chemo)embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention.
    Liu YS; Chuang MT; Tsai YS; Tsai HM; Lin XZ
    Eur Radiol; 2012 Oct; 22(10):2193-200. PubMed ID: 22618520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study.
    Liu YS; Lin CY; Chuang MT; Tsai YS; Wang CK; Ou MC
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):542-552. PubMed ID: 29859998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
    Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC
    World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion.
    de Baere T; Arai Y; Lencioni R; Geschwind JF; Rilling W; Salem R; Matsui O; Soulen MC
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):334-43. PubMed ID: 26390875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
    Idée JM; Guiu B
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma.
    Miraglia R; Pietrosi G; Maruzzelli L; Petridis I; Caruso S; Marrone G; Mamone G; Vizzini G; Luca A; Gridelli B
    World J Gastroenterol; 2007 Jun; 13(21):2952-5. PubMed ID: 17589945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous complications after transcatheter arterial treatment for hepatocellular carcinoma via the internal mammary artery: how to avoid this complication.
    Kajiwara K; Kakizawa H; Takeuchi N; Toyota N; Hieda M; Ishikawa M; Tanitame K; Tani C; Suzuki T; Fujikawa K; Aikata H; Chayama K; Awai K
    Jpn J Radiol; 2011 Jun; 29(5):307-15. PubMed ID: 21717298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
    Favelier S; Boulin M; Hamza S; Cercueil JP; Cherblanc V; Lepage C; Hillon P; Chauffert B; Krausé D; Guiu B
    Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1039-46. PubMed ID: 23224215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation.
    Najmi Varzaneh F; Pandey A; Aliyari Ghasabeh M; Shao N; Khoshpouri P; Pandey P; Zarghampour M; Fouladi D; Liddell R; Anders RA; Kamel IR
    Eur Radiol; 2018 Jul; 28(7):3032-3040. PubMed ID: 29383518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
    Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
    Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization.
    De Santis M; Alborino S; Tartoni PL; Torricelli P; Casolo A; Romagnoli R
    Eur Radiol; 1997; 7(1):10-6. PubMed ID: 9000387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: a preliminary result.
    Park YS; Lee CH; Kim JH; Kim IS; Kiefer B; Seo TS; Kim KA; Park CM
    Magn Reson Imaging; 2014 Jul; 32(6):638-46. PubMed ID: 24703575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure.
    Irie T; Kuramochi M; Takahashi N
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):706-13. PubMed ID: 22996589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumors.
    Wu GC; Chan ED; Chou YC; Yu CY; Hsieh TY; Hsieh CB; Chian CF; Ke FC; Dai YL; Su WL
    Anticancer Drugs; 2014 Sep; 25(8):976-81. PubMed ID: 24736105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
    Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
    Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute respiratory distress syndrome after transcatheter arterial chemoembolization of hepatocellular carcinomas.
    Wu GC; Perng WC; Chen CW; Chian CF; Peng CK; Su WL
    Am J Med Sci; 2009 Nov; 338(5):357-60. PubMed ID: 19826242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases.
    Kenji J; Hyodo I; Tanimizu M; Tanada M; Nishikawa Y; Hosokawa Y; Mandai K; Moriwaki S
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-71-S6-80. PubMed ID: 9151920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.